Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy

Xianyan Chen, Xiaoman Tian, Xuanwei Zhang, Qianyue Deng, Min Wang, Xiaojuan Zhou, Yong Xu, Lin Zhou, Bingwen Zou, Yongmei Liu, Rui Ao, You Lü, Youling GongThoracic 2023 · DOI

TL;DR

This study reveals a strong link between higher doses of radiation to the pericardium and severe lymphopenia (grade 4) in patients with locally advanced esophageal cancer undergoing chemoradiotherapy. This lymphopenia, in turn, appears to negatively impact patient survival, suggesting that careful radiation planning to spare the pericardium could improve outcomes, especially with the rise of immunotherapies.

What Problem Does This Paper Address?

Locally advanced esophageal cancer (LA-EC) is a challenging diagnosis with historically poor survival rates. Concurrent chemoradiotherapy (CCRT) is a standard treatment, but it comes with significant side effects, including lymphopenia, which is a reduction in lymphocytes. Lymphocytes are crucial for immune function, and their depletion can compromise the body's ability to fight cancer. While the link between lymphopenia and poorer outcomes is known, and radiation to organs like the heart and lungs has been associated with adverse effects, the specific role of radiation dose to the pericardium in causing severe lymphopenia and affecting prognosis in LA-EC patients remained unclear. This paper aims to bridge this gap by investigating the relationship between pericardial radiation dose, severe lymphopenia, and patient survival.

Methods

The researchers conducted a retrospective study on 190 patients with LA-EC who received radical CCRT. They employed multivariate analysis (MVA) to identify factors associated with overall survival (OS) and severe lymphopenia. Specifically, they analyzed clinical data and dosimetric parameters derived from dose-volume histograms (DVHs) of organs at risk, including the heart, lungs, and importantly, the pericardium.

To assess the impact of radiation dose on lymphopenia, they used logistic stepwise regression to identify predictors of grade 4 lymphopenia. Based on these findings, they developed and validated a nomogram, a graphical tool that predicts the probability of developing grade 4 lymphopenia. The study also utilized Kaplan-Meier curves and log-rank tests to compare survival outcomes between different groups.

Datasets

The study utilized data from 190 patients with LA-EC treated at two hospitals: West China Hospital and Sichuan Provincial People's Hospital, between February 2011 and April 2021.

  • Training cohort: 100 patients from West China Hospital.
  • Validation cohort: 90 patients from Sichuan Provincial People's Hospital.

No new benchmarks were introduced; the study focused on analyzing existing patient data and treatment records.

Key Insights and Ideas

  • Pericardium is a key player: Unlike previous studies focusing on heart or lung doses, this research highlights the pericardium as a critical organ at risk. Higher radiation doses to the pericardium were strongly associated with severe lymphopenia.
  • Lymphopenia as a prognostic marker: Grade 4 lymphopenia, a significant reduction in lymphocytes, was independently linked to worse overall survival in patients with LA-EC.
  • Predictive modeling for lymphopenia: The study successfully developed a nomogram that can predict the risk of grade 4 lymphopenia based on factors like tumor stage, platelet-to-lymphocyte ratio (PLR), and radiation doses to the heart (HV50) and pericardium (PV30). This tool could help clinicians identify high-risk patients.
  • Implications for immunotherapy: In the era of immune-checkpoint inhibitors (ICIs), which rely on a functional immune system, understanding and mitigating radiation-induced immunosuppression (like lymphopenia) is crucial for optimizing treatment efficacy.

Key Results

  • Higher pericardial V30 (volume of pericardium receiving 30 Gy) was significantly associated with worse overall survival (HR: 1.013, p = 0.039). Patients with PV30 > 55.3% had a median OS of 24.0 months, compared to 54.0 months for those with PV30 ≤ 55.3% (p = 0.004).
  • Grade 4 lymphopenia was an independent predictor of poorer OS (HR: 2.042, p = 0.001). Median OS was 19.0 months for patients with grade 4 lymphopenia versus 54.0 months for those without (p = 0.001).
  • The nomogram for predicting G4 lymphopenia, incorporating stage-IVA, PLR, HV50, and PV30, showed good predictive performance with an AUC of 0.775 for internal validation and 0.843 for external validation.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective design: This introduces potential for selective bias.
  • Relatively small sample size: Despite strict inclusion criteria, the sample size might limit generalizability.
  • Variability in blood count timing: While blood counts were monitored weekly, the exact nadir might not always have been captured precisely.
  • Correlation between cardiac and pericardial doses: The strong correlation between heart and pericardium doses made it challenging to isolate their individual effects, leading to the selection of variables based on AIC for modeling.

Future work suggested includes:

  • Prospective studies: To confirm these findings and establish definitive causal relationships.
  • Larger studies: To investigate a broader range of patients and treatment techniques.
  • Investigating large vessel dosing: To assess its impact on immunosuppression.
  • Optimizing RT regimens: Focusing on conserving the immune system, particularly the pericardial dose, to improve prognosis in the context of immunotherapy.

Summary updated

Abstract

Higher doses of pericardial radiation might affect LA-EC patients' prognosis by inducing G4 lymphopenia during CCRT. Further prospective studies are warranted to confirm these findings, especially in the era of immune-checkpoint inhibitor treatment.
BibTeX
@inproceedings{chen2023pericardial,
  author = {Xianyan Chen and Xiaoman Tian and Xuanwei Zhang and Qianyue Deng and Min Wang and Xiaojuan Zhou and Yong Xu and Lin Zhou and Bingwen Zou and Yongmei Liu and Rui Ao and You Lü and Youling Gong},
  title = {{Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy}},
  booktitle = {Thoracic},
  year = {2023},
  doi = {10.1111/1759-7714.15057},
}
Figure